Abstract
Axonal degeneration in multiple sclerosis (MS) may be caused by mitochondrial dysfunction and is associated with decreased levels of N-acetylaspartate (NAA) as measured with 1H-magnetic resonance spectroscopy (MRS). Fluoxetine stimulates astrocytic glycogenolysis, which serves as an energy source for axons. Eleven patients with MS received fluoxetine orally 20 mg a day during the first week, and 40 mg a day during the second week. The mean NAA/Creatine ratio in cerebral white matter of the MS patients increased from 1.77 at baseline to 1.84 at the end of the second week (p=0.007). These findings show evidence for a reversible axonal dysfunction in patients with MS and provide a rationale for investigating whether fluoxetine has neuroprotective effects in MS.
Original language | English |
---|---|
Pages (from-to) | 22-24 |
Number of pages | 3 |
Journal | Neurosci Lett |
Volume | 402 |
Issue number | 1-2 |
Publication status | Published - Jul 2006 |
Keywords
- Administration
- Oral
- Adult
- Antidepressive Agents
- Second-Generation/*administration & dosage
- Aspartic Acid/*analogs & derivatives/metabolism
- Cerebral Cortex/*drug effects/metabolism
- Creatine/*metabolism
- Female
- Fluoxetine/*administration & dosage
- Humans
- Magnetic Resonance Spectroscopy/methods
- Male
- Middle Aged
- Multiple Sclerosis/drug therapy/*pathology